Who
Thomas Civik
CEO & Chairman of the Board
Company insider
Files Form 4 as: CEO & Chairman of the Board, Pyxis Oncology; Director, Repare Therapeutics; President and CEO, Five Prime Therapeutics; Chief Commercial Officer, Foundation Medicine.
In numbers
- Trades disclosed
- 26
- Buys
- 2
- Sells
- 0
- Bought
- $411K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 1 Jan 2018
- Last trade
- 4 Sep 2026
- Last filed
- 8 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Sep 2026filed 8 Sep 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,503,050 at $0.00 | filing |
| 4 Sep 2026filed 8 Sep 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,503,050 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,956 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,956 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —690,131 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —690,131 at $0.00 | filing |
| 28 Jan 2026filed 28 Jan 2026 | Repare TherapeuticsBiotechnology | SEC FORM 4 Code D | —7,500 | filing |
| 28 Jan 2026filed 28 Jan 2026 | Repare Therapeutics | SEC FORM 4 Code D | —7,500 | filing |
| 31 Mar 2025filed 2 Apr 2025 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | $36K36,979 at $0.98 | filing |
| 17 Jun 2024filed 20 Jun 2024 | Repare Therapeuticsoption or derivative | SEC FORM 4 Code A | —27,200 at $0.00 | filing |
| 26 Mar 2024filed 28 Mar 2024 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | $169K44,024 at $3.83 | filing |
| 8 Jun 2023filed 12 Jun 2023 | Repare Therapeuticsoption or derivative | SEC FORM 4 Code A | —27,200 at $0.00 | filing |
| 24 Mar 2023filed 28 Mar 2023 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Code A | —139,355 at $0.00 | filing |
| 13 May 2022filed 16 May 2022 | Repare Therapeuticsoption or derivative | SEC FORM 4 Code A | —49,000 at $0.00 | filing |
| 31 Mar 2022filed 4 Apr 2022 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Code A | —66,831 at $0.00 | filing |
| 18 Nov 2021filed 19 Nov 2021 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Bought | $200K15,700 at $12.74 | filing |
| 16 Nov 2021filed 18 Nov 2021 | Repare Therapeutics | SEC FORM 4 Bought | $211K7,500 at $28.08 | filing |
| 7 Oct 2021filed 12 Oct 2021 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,191 at $0.00 | filing |
| 7 Sep 2021filed 9 Sep 2021 | Repare Therapeuticsoption or derivative | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 16 Apr 2021filed 19 Apr 2021 | Five Prime Therapeuticsoption or derivative | SEC FORM 4 Code D | —480,000 | filing |
News
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Boardmanilatimes.net · 8 Sep 2026Critical Analysis: Pyxis Oncology (NASDAQ:PYXS) versus Inovio Pharmaceuticals (NASDAQ:INO)PYXS · themarketsdaily.com · 8 Oct 2026
1 headline in the last 90 days name Thomas Civik; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.